Stocktoria
BIOMERICA INC BMRA
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1980-03-17
BIOMERICA INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 9.4% | 11.3% | 8.4% | 15.8% | 5.1% |
| Operating margin | -96.7% | -117.6% | -135.3% | -24.0% | -104.2% |
| Net margin | -93.6% | -110.4% | -133.7% | -24.0% | -103.4% |
| FCF margin | — | -99.9% | -103.7% | -2.8% | -74.8% |
| Return on assets | -83.7% | -64.6% | -49.4% | -39.8% | -63.0% |
| Return on equity | -121.1% | -90.7% | -60.9% | -54.4% | -80.7% |
| Current ratio | 2.80 | 3.51 | 6.58 | 4.69 | 7.10 |
| Revenue growth | -1.9% | 1.4% | -71.7% | 162.1% | 7.6% |
Source: SEC EDGAR filings · CIK 0000073290 · as of 2025-05-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.